TCRX vs TIL

TScan Therapeutics, Inc. vs Instil Bio, Inc. — Valuation Comparison 2026

TCRX

Biological Products, (No Diagnostic Substances)
TScan Therapeutics, Inc.
Quality
6.4
out of 10
Value Trap
24
SAFE
Price
$1.08
Last close
Models
9/13
Active
VS

TIL

Biological Products, (No Diagnostic Substances)
Instil Bio, Inc.
Quality
4.4
out of 10
Value Trap
24
SAFE
Price
$8.07
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType TCRX Fair ValueTCRX Upside TIL Fair ValueTIL Upside
Bayesian DCF Intrinsic $0.68 -36.9% $2.54 -68.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.66 +53.9% $10.34 +28.1%
Dynamic NAV Asset-Based $2.48 +130.0% $12.91 +60.0%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for TCRX vs TIL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TCRX vs TIL — Which Stock Is More Undervalued?

TCRX scores higher with a 6.4/10 quality rating vs TIL's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing TScan Therapeutics, Inc. (TCRX) and Instil Bio, Inc. (TIL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TCRX currently trades at $1.08 with a QOC of 6.4/10, while TIL trades at $8.07 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).